Summary

The global kidney cancer therapeutics and diagnostics market size reached USD 5.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.2 Billion by 2033, exhibiting a growth rate (CAGR) of 5.9% during 2025-2033. The rising incidences of kidney cancer, increasing geriatric population, and favorable initiatives by several governments represent some of the key factors driving the market.

Kidney cancer is a chronic disease where abnormal cell growth occurs in kidney tissues, which turns into tumors. Its symptoms include blood in urine, loss of appetite, flank pain, tiredness, fever, weight loss, bone pain, high blood pressure, and anemia. Kidney cancer is diagnosed through various techniques, such as blood and urine tests, biopsy, biomarker testing, computed tomography (CT) scan, X-ray, magnetic resonance imaging (MRI), cystoscopy, and nephron-ureteroscopy. It can be treated through medications, chemotherapy, radiation therapy, nephrectomy, cryoablation, radiofrequency ablation, and targeted therapy. Kidney cancer therapeutics and diagnostics aid in the removal of cancer cells, destroy tumors and prevent recurring, and assist physicians in planning treatments. They also help in improving kidney function, reducing future complications, controlling cancer spread, and enhancing patient comfort.

Kidney Cancer Therapeutics and Diagnostics Market Trends:
The rising incidences of kidney cancer due to the increasing prevalence of smoking habits, obesity, genetic conditions, and exposure to chemicals is one of the primary factors driving the market growth. Kidney cancer therapeutics and diagnostics are widely used to analyze and treat renal cell carcinoma (RCC), benign kidney tumors, Wilms tumors, transitional cell cancer, renal sarcoma, medullary carcinoma, multilocular cystic RCC, and mucinous tubular and spindle cell carcinoma. Furthermore, the rising geriatric population with high susceptibility to renal cell carcinoma and other forms of kidney cancer is facilitating the demand for therapeutics and diagnostics to manage tumors, prolong survival, and preserve noncancerous parts of the kidney. Additionally, the recent development of diagnostic tools capable of detecting biomarkers, such as baculoviral IAP repeat containing 5 (BIRC5), a key indicator for early detection of clear cell RCC and predicting patient prognosis, is positively influencing the market growth. Apart from this, the introduction of three-dimensional (3D) printing to create pre-operative models of the kidney and its tumors, which, in turn, aids physicians in treatment planning and providing appropriate counseling to the patients, reducing surgical errors, enhancing efficiency, and preserving the majority of kidney functions are favoring the market growth. Moreover, the implementation of various government initiatives to spread awareness regarding cancer is creating a positive outlook for the market. Other factors, including significant growth in the healthcare industry, rising investment in research and development (R&D) activities to identify potential treatment options, and widespread adoption of advanced technologies, such as robotic surgery, telemedicine, and artificial intelligence (AI), are anticipated to drive the market growth further.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global kidney cancer therapeutics and diagnostics market, along with forecasts at the global, regional, and country level from 2025-2033. Our report has categorized the market based on component, cancer types, and application.

Component Insights:

Drugs
Drugs by Therapeutic Class
Targeted Therapy
Immunotherapy
Others
Drugs by Pharmacologic Class
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (II-2)
Diagnostics
Imaging Test
Biopsy
Blood Test
Others

The report has also provided a detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the component. This includes drugs (therapeutic class (targeted therapy, immunotherapy, and others) and pharmacological class (angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies, and cytokine immunotherapy (II-2) and diagnostics (imaging test, biopsy, blood test, and others). According to the report, drugs represented the largest segment.

Cancer Types Insights:

Clear Cell RCC
Papillary RCC
Chromophobe RCC
Transitional Cell Carcinoma
Others

A detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the cancer types has been provided in the report. This includes clear cell RCC, papillary RCC, chromophobe RCC, transitional cell carcinoma, and others. According to the report, clear cell RCC accounted for the largest market share.

Application Insights:

Hospitals
Pharmaceutical Labs
Genomic Laboratories
Others

A detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the application has been provided in the report. This includes hospitals, pharmaceutical labs, genomic laboratories, and others. According to the report, hospitals accounted for the largest market share.

Regional Insights:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for kidney cancer therapeutics and diagnostics. Some of the factors driving the North America kidney cancer therapeutics and diagnostics market include increasing incidences of kidney cancer, rising research and development (R&D) expenditure, increasing geriatric population, etc.

Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global kidney cancer therapeutics and diagnostics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Bristol-Myers Squibb Company, Exelixis Inc., Genentech Inc. (Roche Holding AG), Novartis AG, Pfizer Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:
How has the global kidney cancer therapeutics and diagnostics market performed so far and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global kidney cancer therapeutics and diagnostics market?
What are the key regional markets?
Which countries represent the most attractive kidney cancer therapeutics and diagnostics markets?
What is the breakup of the market based on the component?
What is the breakup of the market based on the cancer types?
What is the breakup of the market based on the application?
What is the competitive structure of the global kidney cancer therapeutics and diagnostics market?
Who are the key players/companies in the global kidney cancer therapeutics and diagnostics market?

ページTOPに戻る

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Kidney Cancer Therapeutics and Diagnostics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Component
6.1 Drugs
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Drugs by Therapeutic Class
6.1.2.1.1 Targeted Therapy
6.1.2.1.2 Immunotherapy
6.1.2.1.3 Others
6.1.2.2 Drugs by Pharmacologic Class
6.1.2.2.1 Angiogenesis Inhibitors
6.1.2.2.2 mTOR Inhibitors
6.1.2.2.3 Monoclonal Antibodies
6.1.2.2.4 Cytokine Immunotherapy (II-2)
6.1.3 Market Forecast
6.2 Diagnostics
6.2.1 Market Trends
6.2.2 Key Segments
6.2.2.1 Imaging Test
6.2.2.2 Biopsy
6.2.2.3 Blood Test
6.2.2.4 Others
6.2.3 Market Forecast
7 Market Breakup by Cancer Types
7.1 Clear Cell RCC
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Papillary RCC
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Chromophobe RCC
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Transitional Cell Carcinoma
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by Application
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Pharmaceutical Labs
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Genomics Laboratories
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Bristol-Myers Squibb Company
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Exelixis Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Genentech Inc. (Roche Holding AG)
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 SWOT Analysis
14.3.4 Novartis AG
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Pfizer Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

​Figure 1: Global: Kidney Cancer Therapeutics and Diagnostics Market: Major Drivers and Challenges
Figure 2: Global: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 4: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Component (in %), 2024
Figure 5: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Cancer Types (in %), 2024
Figure 6: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Application (in %), 2024
Figure 7: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Region (in %), 2024
Figure 8: Global: Kidney Cancer Therapeutics and Diagnostics (Drugs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 9: Global: Kidney Cancer Therapeutics and Diagnostics (Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 10: Global: Kidney Cancer Therapeutics and Diagnostics (Diagnostics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 11: Global: Kidney Cancer Therapeutics and Diagnostics (Diagnostics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 12: Global: Kidney Cancer Therapeutics and Diagnostics (Clear Cell RCC) Market: Sales Value (in Million USD), 2019 & 2024
Figure 13: Global: Kidney Cancer Therapeutics and Diagnostics (Clear Cell RCC) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 14: Global: Kidney Cancer Therapeutics and Diagnostics (Papillary RCC) Market: Sales Value (in Million USD), 2019 & 2024
Figure 15: Global: Kidney Cancer Therapeutics and Diagnostics (Papillary RCC) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 16: Global: Kidney Cancer Therapeutics and Diagnostics (Chromophobe RCC) Market: Sales Value (in Million USD), 2019 & 2024
Figure 17: Global: Kidney Cancer Therapeutics and Diagnostics (Chromophobe RCC) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 18: Global: Kidney Cancer Therapeutics and Diagnostics (Transitional Cell Carcinoma) Market: Sales Value (in Million USD), 2019 & 2024
Figure 19: Global: Kidney Cancer Therapeutics and Diagnostics (Transitional Cell Carcinoma) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 20: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
Figure 21: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 22: Global: Kidney Cancer Therapeutics and Diagnostics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
Figure 23: Global: Kidney Cancer Therapeutics and Diagnostics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 24: Global: Kidney Cancer Therapeutics and Diagnostics (Pharmaceutical Labs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 25: Global: Kidney Cancer Therapeutics and Diagnostics (Pharmaceutical Labs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 26: Global: Kidney Cancer Therapeutics and Diagnostics (Genomics Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
Figure 27: Global: Kidney Cancer Therapeutics and Diagnostics (Genomics Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 28: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
Figure 29: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 30: North America: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 31: North America: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 32: United States: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 33: United States: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 34: Canada: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 35: Canada: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 36: Asia-Pacific: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 37: Asia-Pacific: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 38: China: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 39: China: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 40: Japan: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 41: Japan: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 42: India: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 43: India: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 44: South Korea: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 45: South Korea: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 46: Australia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 47: Australia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 48: Indonesia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 49: Indonesia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 50: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 51: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 52: Europe: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 53: Europe: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 54: Germany: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 55: Germany: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 56: France: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 57: France: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 58: United Kingdom: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 59: United Kingdom: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 60: Italy: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 61: Italy: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 62: Spain: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 63: Spain: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 64: Russia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 65: Russia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 66: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 67: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 68: Latin America: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 69: Latin America: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 70: Brazil: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 71: Brazil: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 72: Mexico: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 73: Mexico: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 74: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 75: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 76: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
Figure 77: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Country (in %), 2024
Figure 78: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 79: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Drivers, Restraints, and Opportunities
Figure 80: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Value Chain Analysis
Figure 81: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Kidney Cancer Therapeutics and Diagnostics Market: Key Industry Highlights, 2024 & 2033
Table 2: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Component (in Million USD), 2025-2033
Table 3: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Cancer Types (in Million USD), 2025-2033
Table 4: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Application (in Million USD), 2025-2033
Table 5: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 6: Global: Kidney Cancer Therapeutics and Diagnostics Market: Competitive Structure
Table 7: Global: Kidney Cancer Therapeutics and Diagnostics Market: Key Players